Parallel factor analysis of ovarian autofluorescence as a cancer diagnostic

Lasers in Surgery and Medicine

Volumn 44, Issue 4, 2012, Pages 282-295

  George, Ronie ^a   Michaelides, Michalis ^b   Brewer, Molly A ^c   Utzinger, Urs ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b University of Arizona   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

endogenous fluorescence; excitation emission matrix; ovarian cancer risk status; tissue optical spectroscopy; UVC excitation

Indexed keywords

ADULT; AGED; ARTICLE; ATOMIC EMISSION SPECTROMETRY; AUTOFLUORESCENCE; CANCER DIAGNOSIS; CANCER RISK; ENDOMETRIOSIS; FEMALE; HUMAN; HUMAN TISSUE; MENOPAUSE; OUTCOME ASSESSMENT; OVARIECTOMY; OVARY CANCER; PARALLEL DESIGN; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BIOPSY; FACTOR ANALYSIS, STATISTICAL; FEMALE; FLUORESCENCE; HUMANS; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; OVARY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, FLUORESCENCE; YOUNG ADULT;

EID: 84859759688     PISSN: 01968092     EISSN: 10969101     Source Type: Journal    
DOI: 10.1002/lsm.22014     Document Type: Article

References (75)

1. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope RC, Wilson TO, Podratz KC, Cliby WA,. Quality improvement in the surgical approach to advanced ovarian cancer: The Mayo Clinic experience. J Am Coll Surg 2009; 208 (4): 614-620.
2. Bandera EV, Kushi LH, Rodriguez-Rodriguez L,. Nutritional factors in ovarian cancer survival. Nutr Cancer 2009; 61 (5): 580-586.
3. Howlader N, Noone AM, Krapco M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK,. SEER Cancer Statistics Review, 1975-2008. Volume 2011. Bethesda, MD: National Cancer Institute; 2011.
4. Hoskins WJ,. Prospective on ovarian cancer: Why prevent? J Cell Biochem Suppl 1995; 23: 189-199.
5. Kobel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, Gilks CB,. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 2010; 29 (3): 203-211.
6. Kobel M, Kalloger SE, Santos JL, Huntsman DG, Gilks CB, Swenerton KD,. Tumor type and substage predict survival in stage I and II ovarian carcinoma: Insights and implications. Gynecol Oncol 2010; 116 (1): 50-56.
7. Brewer MA, Utzinger U, Barton JK, Hoying JB, Kirkpatrick ND, Brands WR, Davis JR, Hunt K, Stevens SJ, Gmitro AF,. Imaging of the ovary. Technol Cancer Res Treat 2004; 3 (6): 617-627.
8. Holschneider CH, Berek JS,. Ovarian cancer: Epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000; 19 (1): 3-10.
9. Shaw PA, Rouzbahman M, Pizer ES, Pintilie M, Begley H,. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod Pathol 2009; 22 (9): 1133-1138.
10. Clarke-Pearson DL,. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009; 361 (2): 170-177.
11. Tortolero-Luna G, Mitchell MF,. The epidemiology of ovarian cancer. J Cell Biochem Suppl 1995; 23: 200-207.
12. Kleinsmith LJ,. Principles of Cancer Biology. San Francisco: Pearson Benjamin Cummings; 2006.
13. Rabinerson D, Kaplan B, Levavi H, Neri A,. The biology of ovarian cancer of epithelial origin. Isr J Med Sci 1996; 32 (11): 1128-1133.
14. Tanbakuchi AA, Rouse AR, Udovich JA, Hatch KD, Gmitro AF,. Clinical confocal microlaparoscope for real-time in vivo optical biopsies. J Biomed Opt 2009; 14 (4): 044030.
15. Schapira MM, Matchar DB, Young MJ,. The effectiveness of ovarian-cancer screening-A decision-analysis model. Ann Intern Med 1993; 118 (11): 838-843.
16. Greene MH, Feng Z, Gail MH,. The importance of test positive predictive value in ovarian cancer screening. Clin Cancer Res 2008; 14 (22): 7574, author reply 7577-7579.
17. Jacobs IJ, Menon U,. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004; 3 (4): 355-3366.
18. Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB,. CA 125: The past and the future. Int J Biol Markers 1998; 13 (4): 179-187.
19. Bagan P, Berna P, Assouad J, Hupertan V, Le Pimpec Barthes F, Riquet M,. Value of cancer antigen 125 for diagnosis of pleural endometriosis in females with recurrent pneumothorax. Eur Respir J 2008; 31 (1): 140-142.
20. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC,. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68 (5): 1331-1337.
21. Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, Soper JT, Clarke-Pearson DL, Oram DH, Bast RC Jr. , Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 1993; 85 (21): 1748-1751.
22. Woolas RP, Conaway MR, Xu FJ, Jacobs IJ, Yu YH, Daly L, Davies AP, Obriant K, Berchuck A, Soper JT, Clarkepearson DL, Rodriguez G, Oram DH, Bast RC,. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 1995; 59 (1): 111-116.
23. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW,. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64 (16): 5882-5890.
24. Bast RC Jr, Urban N, Shridhar V, Smith D, Zhang Z, Skates S, Lu K, Liu J, Fishman D, Mills G,. Early detection of ovarian cancer: Promise and reality. Cancer Treat Res 2002; 107: 61-97.
25. Togashi K,. Ovarian cancer: The clinical role of US, CT, and MRI. Eur Radiol 2003; 13 (Suppl 4): L87-L104.
26. Lu KH, Skates S, Bevers TB, Newland W, Moore RG, Leeds L, Harris S, Adeyinka OW, Fritsche HA, Bast RC,. A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA). J Clin Oncol (Meeting Abstracts) 2010; 28 (15 suppl) 5003.
27. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC Jr, Lokshin AE,. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010; 28 (13): 2159-2166.
28. Kirkpatrick ND, Brewer MA, Utzinger U,. Endogenous optical biomarkers of ovarian cancer evaluated with multiphoton microscopy. Cancer Epidemiol Biomarkers Prev 2007; 16 (10): 2048-2057.
29. Nadiarnykh O, LaComb RB, Brewer MA, Campagnola PJ,. Alterations of the extracellular matrix in ovarian cancer studied by Second Harmonic Generation imaging microscopy. BMC Cancer 2010; 10: 94.
30. Brewer M, Utzinger U, Silva E, Gershenson D, Bast RC Jr, Follen M, Richards-Kortum R,. Fluorescence spectroscopy for in vivo characterization of ovarian tissue. Lasers Surg Med 2001; 29 (2): 128-135.
31. Kamath SD, Bhat RA, Ray S, Mahato KK,. Autofluorescence of normal, benign, and malignant ovarian tissues: A pilot study. Photomed Laser Surg 2009; 27 (2): 325-335.
32. Evans CL, Rizvi I, Hasan T, de Boer JF,. In vitro ovarian tumor growth and treatment response dynamics visualized with time-lapse OCT imaging. Opt Express 2009; 17 (11): 8892-8906.
33. Hariri LP, Bonnema GT, Schmidt K, Winkler AM, Korde V, Hatch KD, Davis JR, Brewer MA, Barton JK,. Laparoscopic optical coherence tomography imaging of human ovarian cancer. Gynecol Oncol 2009; 114 (2): 188-194.
34. Ramanujam N,. Fluorescence spectroscopy in vivo. In:, Meyers RA, editor. Encyclopedia of Analytical Chemistry. San Francisco, CA: John Wiley & Sons Ltd; 2000. pp 20-56.
35. Ramanujam N,. Fluorescence spectroscopy of neoplastic and non-neoplastic tissues. Neoplasia (New York) 2000; 2 (1-2): 89-117.
36. Chance B,. Optical method. Ann Rev Biophys Biophys Chem 1991; 20: 1-28.
37. Wang HW, Wei YH, Guo HW,. Reduced nicotinamide adenine dinucleotide (NADH) fluorescence for the detection of cell death. Anticancer Agents Med Chem 2009; 9 (9): 1012-1017.
38. Lakowicz JR,. Principles of Fluorescence Spectroscopy. New York: Kluwer Academic/Plenum; 1999. xxiii, 698 p.
39. Kirkpatrick ND, Hoying JB, Botting SK, Weiss JA, Utzinger U,. In vitro model for endogenous optical signatures of collagen. J Biomed Opt 2006; 11 (5): 054021.
40. Berry DA, Iversen ES Jr, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani G,. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes [see comment]. J Clin Oncol 2002; 20 (11): 2701-2712.
41. Shah CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, Andersen MR, Scholler N, Bergan LA, Thorpe JD, Urban N, Drescher CW,. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol Biomarkers Prev 2009; 18 (5): 1365-1372.
42. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G,. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378 (6559): 789-792.
43. Woodruff JD, Julian CG,. Multiple malignancies in the upper genital canal. Am J Obstet Gynecol 1969; 93: 22.
44. George R, Chandrasekaran A, Brewer MA, Hatch KD, Utzinger U,. A clinical research device for ovarian cancer detection by optical spectroscopy in the ultraviolet C-visible. J Biomed Opt 2010; 15 (5): 14.
45. Jolliffe IT,. Principal Component Analysis. New York: Springer; 2002.
46. Andersson CA, Bro R,. The N-way toolbox for MATLAB. Chemom Intell Lab Syst 2000; 52 (1): 1-4.
47. Harshman RA,. Foundations of the PARAFAC procedure: Models and conditions for an explanatory multimodal factor analysis. UCLA Working Papers in Phonetics 1970; 16: 1-84.
48. Bro R,. PARAFAC. Tutorial and applications. Chemom Intell Lab Syst 1997; 38: 149-171.
49. Harshman RA, Lundy ME,. PARAFAC: Parallel Factor Analysis. Comput Stat Data Anal 1994; 18:(1): 39-72.
50. Bro R, Kiers HAL,. A new efficient method for determining the number of components in PARAFAC models. J Chemom 2003; 17: 274-286.
51. Bro R,. Multi-Way Analysis in the Food Industry: Models, Algorithms, and Applications. Denmark: Royal Veterinary and Agricultural University; 1998.
52. Dorfman DD, Berbaum KS, Metz CE,. Receiver operating characteristic rating analysis. Generalization to the population of readers and patients with the jackknife method. Invest Radiol 1992; 27 (9): 723-731.
53. DaCosta RS, Andersson H, Wilson BC,. Molecular fluorescence excitation-emission matrices relevant to tissue spectroscopy. Photochem Photobiol 2003; 78 (4): 384-392.
54. Dixon JM, Taniguchi M, Lindsey JS,. PhotochemCAD 2: A refined program with accompanying spectral databases for photochemical calculations. Photochem Photobiol 2005; 81 (1): 212-213.
55. Kirkpatrick ND, Zou CP, Brewer MA, Brands WR, Drezek RA, Utzinger U,. Endogenous fluorescence spectroscopy of cell suspensions for chemopreventive drug monitoring. Photochem Photobiol 2005; 81 (1): 125-134.
56. Czeczuga-Semeniuk E, Wolczynski S,. Does variability in carotenoid composition and concentration in tissues of the breast and reproductive tract in women depend on type of lesion? Adv Med Sci 2008; 53 (2): 270-277.
57. Drezek R, Sokolov K, Utzinger U, Boiko I, Malpica A, Follen M, Richards-Kortum R,. Understanding the contributions of NADH and collagen to cervical tissue fluorescence spectra: Modeling, measurements, and implications. J Biomed Opt 2001; 6 (4): 385-396.
58. Muller MG, Georgakoudi I, Zhang Q, Wu J, Feld MS,. Intrinsic fluorescence spectroscopy in turbid media: Disentangling effects of scattering and absorption. Appl Opt 2001; 40 (25): 4633-4646.
59. Georgakoudi I, Jacobson BC, Van Dam J, Backman V, Wallace MB, Muller MG, Zhang Q, Badizadegan K, Sun D, Thomas GA, Perelman LT, Feld MS,. Fluorescence, reflectance, and light-scattering spectroscopy for evaluating dysplasia in patients with Barrett's esophagus. Gastroenterology 2001; 120 (7): 1620-1629.
60. Georgakoudi I, Sheets EE, Muller MG, Backman V, Crum CP, Badizadegan K, Dasari RR, Feld MS,. Trimodal spectroscopy for the detection and characterization of cervical precancers in vivo. Am J Obstet Gynecol 2002; 186 (3): 374-382.
61. Palmer GM, Zhu C, Breslin TM, Xu F, Gilchrist KW, Ramanujam N,. Comparison of multiexcitation fluorescence and diffuse reflectance spectroscopy for the diagnosis of breast cancer (March 2003). IEEE Trans Biomed Eng 2003; 50 (11): 1233-1242.
62. Skala MC, Palmer GM, Vrotsos KM, Gendron-Fitzpatrick A, Ramanujam N,. Comparison of a physical model and principal component analysis for the diagnosis of epithelial neoplasias in vivo using diffuse reflectance spectroscopy. Opt Express 2007; 15 (12): 7863-7875.
63. Pavlova I, Sokolov K, Drezek R, Malpica A, Follen M, Richards-Kortum R,. Microanatomical and biochemical origins of normal and precancerous cervical autofluorescence using laser-scanning fluorescence confocal microscopy. Photochem Photobiol 2003; 77 (5): 550-555.
64. Georgakoudi I, Jacobson BC, Muller MG, Sheets EE, Badizadegan K, Carr-Locke DL, Crum CP, Boone CW, Dasari RR, Van Dam J, Feld MS,. NAD(P)H and collagen as in vivo quantitative fluorescent biomarkers of epithelial precancerous changes. Cancer Res 2002; 62 (3): 682-687.
65. Arifler D, Pavlova I, Gillenwater A, Richards-Kortum R,. Light scattering from collagen fiber networks: Micro-optical properties of normal and neoplastic stroma. Biophys J 2007; 92 (9): 3260-3274.
66. McCluggage WG,. Mullerian adenosarcoma of the female genital tract. Adv Anat Pathol 2010; 17 (2): 122-129.
67. Manoharan M, Azmi MA, Soosay G, Mould T, Weekes AR,. Mullerian adenosarcoma of uterine cervix: Report of three cases and review of literature. Gynecol Oncol 2007; 105 (1): 256-260.
68. Kah JC, Lau WK, Tan PH, Sheppard CJ, Olivo M,. Endoscopic image analysis of photosensitizer fluorescence as a promising noninvasive approach for pathological grading of bladder cancer in situ. J Biomed Opt 2008; 13 (5): 054022.
69. Sokolov K, Galvan J, Myakov A, Lacy A, Lotan R, Richards-Kortum R,. Realistic three-dimensional epithelial tissue phantoms for biomedical optics. J Biomed Opt 2002; 7 (1): 148-156.
70. Ramanujam N, Mitchell MF, Mahadevan A, Warren S, Thomsen S, Silva E, Richards-Kortum R,. In vivo diagnosis of cervical intraepithelial neoplasia using 337-nm-excited laser-induced fluorescence. Proc Natl Acad Sci USA 1994; 91 (21): 10193-10197.
71. Schomacker KT, Meese TM, Jiang C, Abele CC, Dickson K, Sum ST, Flewelling RF,. Novel optical detection system for in vivo identification and localization of cervical intraepithelial neoplasia. J Biomed Opt 2006; 11 (3): 34009.
72. Brewer MA, Johnson K, Follen M, Gershenson D, Bast R Jr. , Prevention of ovarian cancer: Intraepithelial neoplasia. Clin Cancer Res 2003; 9 (1): 20-30.
73. Hung J, Lam S, LeRiche JC, Palcic B,. Autofluorescence of normal and malignant bronchial tissue. Las Surg Med 1991; 11: 99-105.
74. Altman DG, Bland JM,. Diagnostic-tests-2-Predictive values 4. Br Med J 1994; 309 (6947): 102-102.
75. Chatterjee M, Mohapatra S, Ionan A, Bawa G, Ali-Fehmi R, Wang X, Nowak J, Ye B, Nahhas FA, Lu K, Witkin SS, Fishman D, Munkarah A, Morris R, Levin NK, Shirley NN, Tromp G, Abrams J, Draghici S, Tainsky MA,. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res 2006; 66 (2): 1181-1190.